ישראל - עברית - Ministry of Health

אלסמד מערכות רפואיות בע"מ - צוות טכני - דימות אולטרהסאונד

ישראל - עברית - Ministry of Health

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

ישראל - עברית - Ministry of Health

neopharm scientific ltd - cannabidiol drug substance ( cbd bds ); delta-9-tetrahydrocannabinol drug substance ( thc bds ) - ספריי לחלל הפה - cannabidiol drug substance ( cbd bds ) 25 mg / 1 ml; delta-9-tetrahydrocannabinol drug substance ( thc bds ) 27 mg / 1 ml - nabiximols - sativex is indicated, as add-on treatment, for symptom relief in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other medication and who demonstrate at least 20 % improvement in spasticity related symptoms during a four week trial of therapy.sativex is indicated as adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis in adults.

ישראל - עברית - Ministry of Health

comex ltd - meloxicam - תמיסה להזרקה - meloxicam 5 mg/ml - dogs: alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.cats:reduction of post operative pain after ovrariohysterectomy and minor soft tissue surgery.

ישראל - עברית - Ministry of Health

medomie pharma ltd, israel - teriflunomide - טבליות מצופות פילם - teriflunomide 14 mg - teriflunomide

ישראל - עברית - Ministry of Health

medison pharma ltd - dextromethorphan hydrobromide; quinidine sulfate - קפסולות - quinidine sulfate 10 mg; dextromethorphan hydrobromide 20 mg - quinidine - quinidine - for the treatment of pseudobulbar affect (pba) in als and ms patients only.

ישראל - עברית - Ministry of Health

medison pharma ltd - interferon beta 1a 30 mcg/vial - powder for solution for injection - interferon beta-1a - avonex is indicated for the treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. avonex is also indicated for the treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

ישראל - עברית - Ministry of Health

medison pharma ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 30 mcg / 0.5 ml - interferon beta-1a - interferon beta-1a - treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

ישראל - עברית - Ministry of Health

bayer israel ltd - interferon beta 1b - אבקה וממס להכנת תמיסה להזרקה - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

ישראל - עברית - Ministry of Health

novartis israel ltd - fingolimod as hydrochloride - קפסולה קשיחה - fingolimod as hydrochloride 0.5 mg - fingolimod - fingolimod - gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( ms ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disabiliry.